CEREVEL THERAPEUTICS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.6 USD | +0.70% |
|
-1.21% | -1.89% |
| 12:36pm | Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study | RE |
| Mar. 25 | Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation | MT |
Presentation Operator MessageOperator (Operator)Good morning. Welcome to the Cerevel Therapeut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâs disease psychosis, epilepsy, panic disorder and Parkinsonâs disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinsonâs disease.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
41.6
USD
Average target price
44.78
USD
Spread / Average Target
+7.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.89% | 7.55B | |
| -3.39% | 102B | |
| +2.61% | 96.84B | |
| -0.93% | 21.48B | |
| -18.14% | 20.82B | |
| -7.26% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B |
- Stock Market
- Equities
- CERE Stock
- News Cerevel Therapeutics Holdings, Inc.
- Transcript : Cerevel Therapeutics Holdings, Inc., Q2 2021 Earnings Call, Aug 11, 2021
